Literature DB >> 29526023

Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol.

Rachel I Anderson1,2, David E Moorman3, Howard C Becker4,5,6,7.   

Abstract

Understanding the neural systems that drive alcohol motivation and are disrupted in alcohol use disorders is of critical importance in developing novel treatments. The dynorphin and orexin/hypocretin neuropeptide systems are particularly relevant with respect to alcohol use and misuse. Both systems are strongly associated with alcohol-seeking behaviors, particularly in cases of high levels of alcohol use as seen in dependence. Furthermore, both systems also play a role in stress and anxiety, indicating that disruption of these systems may underlie long-term homeostatic dysregulation seen in alcohol use disorders. These systems are also closely interrelated with one another - dynorphin/kappa opioid receptors and orexin/hypocretin receptors are found in similar regions and hypocretin/orexin neurons also express dynorphin - suggesting that these two systems may work together in the regulation of alcohol seeking and may be mutually disrupted in alcohol use disorders. This chapter reviews studies demonstrating a role for each of these systems in motivated behavior, with a focus on their roles in regulating alcohol-seeking and self-administration behaviors. Consideration is also given to evidence indicating that these neuropeptide systems may be viable targets for the development of potential treatments for alcohol use disorders.

Entities:  

Keywords:  Alcohol; Dynorphin; Ethanol; Hypocretin; Kappa opioid receptor; Orexin

Mesh:

Substances:

Year:  2018        PMID: 29526023      PMCID: PMC7003671          DOI: 10.1007/164_2018_100

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  231 in total

Review 1.  Orexins and fear: implications for the treatment of anxiety disorders.

Authors:  África Flores; Rocío Saravia; Rafael Maldonado; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2015-07-24       Impact factor: 13.837

2.  Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2.

Authors:  Diane L Rosin; Matthew C Weston; Charles P Sevigny; Ruth L Stornetta; Patrice G Guyenet
Journal:  J Comp Neurol       Date:  2003-10-27       Impact factor: 3.215

3.  Binge-like consumption of ethanol and other salient reinforcers is blocked by orexin-1 receptor inhibition and leads to a reduction of hypothalamic orexin immunoreactivity.

Authors:  Jeffrey J Olney; Montserrat Navarro; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2015-01       Impact factor: 3.455

4.  Role of κ-Opioid Receptors in the Bed Nucleus of Stria Terminalis in Reinstatement of Alcohol Seeking.

Authors:  A D Lê; Douglas Funk; Kathleen Coen; Sahar Tamadon; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2017-06-07       Impact factor: 7.853

5.  Presynaptic inhibition of gamma-aminobutyric acid release in the bed nucleus of the stria terminalis by kappa opioid receptor signaling.

Authors:  Chia Li; Kristen E Pleil; Alice M Stamatakis; Steven Busan; Linh Vong; Bradford B Lowell; Garret D Stuber; Thomas L Kash
Journal:  Biol Psychiatry       Date:  2012-01-05       Impact factor: 13.382

6.  Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area.

Authors:  Nicole M Vittoz; Craig W Berridge
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

7.  Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus.

Authors:  Jessica R Barson; Kinning Poon; Hui Tin Ho; Mohammad I Alam; Lilia Sanzalone; Sarah F Leibowitz
Journal:  Addict Biol       Date:  2015-07-29       Impact factor: 4.280

8.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Authors:  Elyssa B Margolis; Hagar Lock; Vladimir I Chefer; Toni S Shippenberg; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.

Authors:  R F Mucha; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Effect of Orexin A antagonist (SB-334867) infusion into the nucleus accumbens on consummatory behavior and alcohol preference in Wistar rats.

Authors:  Santosh Mayannavar; K S Rashmi; Yalla Durga Rao; Saraswati Yadav; B Ganaraja
Journal:  Indian J Pharmacol       Date:  2016 Jan-Feb       Impact factor: 1.200

View more
  5 in total

1.  Central Orexin A Affects Reproductive Axis by Modulation of Hypothalamic Kisspeptin/Neurokinin B/Dynorphin Secreting Neurons in the Male Wistar Rats.

Authors:  Abdolkarim Hosseini; Homayoun Khazali
Journal:  Neuromolecular Med       Date:  2018-09-14       Impact factor: 3.843

2.  Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice.

Authors:  Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

3.  Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice.

Authors:  Harold L Haun; William C Griffin; Marcelo F Lopez; Howard C Becker
Journal:  Neuropharmacology       Date:  2020-02-02       Impact factor: 5.250

Review 4.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203

5.  Blockade of Orexin Receptors in the Posterior Paraventricular Nucleus of the Thalamus Prevents Stress-Induced Reinstatement of Reward-Seeking Behavior in Rats With a History of Ethanol Dependence.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Front Integr Neurosci       Date:  2020-11-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.